Agency Forms Undergoing Paperwork Reduction Act Review, 57757-57758 [2017-26399]
Download as PDF
<![CDATA[
57757
Federal Register / Vol. 82, No. 234 / Thursday, December 7, 2017 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–17–17ACE]
Agency Forms Undergoing Paperwork
Reduction Act Review
sradovich on DSK3GMQ082PROD with NOTICES
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled MedicationAssisted Treatment (MAT) for Opioid
Use Disorders Study to the Office of
Management and Budget (OMB) for
review and approval. CDC previously
published a ‘‘Proposed Data Collection
Submitted for Public Comment and
Recommendations’’ notice on June, 19,
2017 to obtain comments from the
public and affected agencies. CDC
received three comments related to the
previous notice. This notice serves to
allow an additional 30 days for public
and affected agency comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570 or
send an email to omb@cdc.gov. Direct
written comments and/or suggestions
regarding the items contained in this
notice to the Attention: CDC Desk
Officer, Office of Management and
Budget, 725 17th Street NW.,
Washington, DC 20503 or by fax to (202)
395–5806. Provide written comments
within 30 days of notice publication.
Proposed Project
Evaluation of Medication-Assisted
Treatment (MAT) for Opioid Use
Disorder—New—National Center for
Injury Prevention and Control (NCIPC),
Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
This is a new Information Collection
Request. CDC requests a three-year OMB
approval.
About 2 million people aged 12 or
older in the United States have Opioid
Use Disorders (OUDs) related to
prescription opioids and almost 600,000
have OUDs related to heroin use
(SAMHSA, 2015). OUD is a problematic
pattern of opioid use that cause
significant impairment or distress
characterized by unsuccessful efforts to
control use and failures to fulfill
obligations social, at work, or school,
yet many of these people do not receive
OUD treatment. Given the continued
need for treatment and the urgency of
the opioid epidemic, further
understanding of the individual and
contextual factors that may impact
treatment outcomes is needed. To help
address this need, the CDC is
conducting a study of 60 Opioid Use
Disorder (OUD) treatment facilities and
four primary care facilities located in 11
metropolitan statistical areas across the
United States. The respondent universe
includes individuals in the United
States who receive some form of OUD
treatment in the 11 MSAs.
Prospective participants will be
eligible if they are 18 to 64 years of age
and initiating one of four primary
treatments for OUD: Methadone
maintenance treatment (MMT),
buprenorphine (BUP), naltrexone
(NTX), or counseling treatment without
medication (COUN). The study aims to
enroll 3,560 clients across all sites to
better understand the relationship
between type of Medication Assisted
Treatment (MAT) and individual and
treatment facility characteristics, and
contextual factors.
The information gained from this data
collection will help inform policy
makers, communities, and providers on
how individual characteristics and
contextual factors may impact client
outcomes. The MAT study will also
provide a unique perspective for three
reasons: (1) It assesses the treatment,
individual, and contextual factors that
influence implementation and outcomes
in real-world settings; (2) its large target
sample size (n = 3,560); and, (3) the long
follow-up window (i.e., 24-month
follow-up period with clients). CDC has
collaborated with other relevant federal
agencies to avoid duplication and
maximize efficiencies in data collection.
The MAT Study design and protocols
have been reviewed and shared with
colleagues from the Substance Abuse
and Mental Health Services
Administration (SAMHSA) and the
National Institute on Drug Abuse
(NIDA).
Four overarching evaluation questions
guide the MAT Study. These questions
drive the research design, and CDC
developed this data collection effort to,
specifically, address these evaluation
questions. This data collection effort
captures a series of outcome measures
including the associated benefits (e.g.,
reductions in morbidity, mortality, and
drug overdoses; improvements in
socioeconomic outcomes and healthrelated quality of life [HRQOL]) and
potential risks (e.g., side effects,
diversion potential) of each treatment
alternative.
The study will use a mixed-methods
approach using quantitative methods
such as multilevel latent growth models,
propensity score matching, latent class
analysis and advanced mediation
analysis and qualitative methods such
as interactive coding and analysis for
common themes.
The total estimated annualized
burden for this collection is 3,093 hours.
The only cost to respondents will be
time spent responding to the surveys.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Type of respondents
Form name
Clients .............................................................
Client Screener ..............................................
Client Check-In ...............................................
VerDate Sep<11>2014
18:50 Dec 06, 2017
Jkt 244001
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
E:\FR\FM\07DEN1.SGM
1,583
1,187
07DEN1
Number of
responses per
respondent
1
2
Average
burden per
response
(in hours)
5/60
15/60
57758
Federal Register / Vol. 82, No. 234 / Thursday, December 7, 2017 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS—Continued
Number of
respondents
Type of respondents
Form name
Treatment facility staff .....................................
Client Questionnaire Baseline ........................
Client Questionnaire 12-Month Follow-up .....
Client Questionnaire 24-Month Follow-up .....
Client Focus Groups ......................................
Staff Focus Groups ........................................
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
[FR Doc. 2017–26399 Filed 12–6–17; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket Number CDC–2017–0104, NIOSH–
304]
Draft—National Occupational Research
Agenda for Traumatic Injury
Prevention
National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC),
Department of Health and Human
Services (HHS).
ACTION: Request for comment.
AGENCY:
The National Institute for
Occupational Safety and Health of the
Centers for Disease Control and
Prevention announces the availability of
a draft NORA Agenda entitled National
Occupational Research Agenda for
Traumatic Injury Prevention for public
comment. To view the notice and
related materials, visit https://
www.regulations.gov. and enter CDC–
2017–0104 in the search field and click
‘‘Search.’’
SUMMARY:
sradovich on DSK3GMQ082PROD with NOTICES
Table of Contents
•
•
•
•
•
Dates
Addresses
For Further Information Contact
Supplementary Information
Background
Electronic or written comments
must be received by February 5, 2018.
ADDRESSES: You may submit comments,
identified by CDC–2017–0104 and
docket number NIOSH–304, by any of
the following methods:
DATES:
VerDate Sep<11>2014
18:50 Dec 06, 2017
Jkt 244001
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: National Institute for
Occupational Safety and Health, NIOSH
Docket Office, 1090 Tusculum Avenue,
MS C–34, Cincinnati, Ohio 45226–1998.
Instructions: All submissions received
in response to this notice must include
the agency name and docket number
[CDC–2017–0104; NIOSH–304]. All
relevant comments received will be
posted without change to https://
www.regulations.gov, including any
personal information provided. For
access to the docket to read background
documents or comments received, go to
https://www.regulations.gov. All
information received in response to this
notice will also be available for public
examination and copying at the NIOSH
Docket Office, 1150 Tusculum Avenue,
Room 155, Cincinnati, OH 45226–1998.
FOR FURTHER INFORMATION CONTACT:
Emily Novicki (NORACoordinator@
cdc.gov), National Institute for
Occupational Safety and Health, Centers
for Disease Control and Prevention,
Mailstop E–20, 1600 Clifton Road NE.,
Atlanta, GA 30329, phone (404) 498–
2581 (not a toll free number).
SUPPLEMENTARY INFORMATION: The
National Occupational Research Agenda
(NORA) is a partnership program
created to stimulate innovative research
and improved workplace practices. The
national agenda is developed and
implemented through the NORA sector
and cross-sector councils. Each council
develops and maintains an agenda for
its sector or cross-sector.
Background: The National
Occupational Research Agenda for
Traumatic Injury Prevention (the
Agenda) is intended to identify the
research, information, and actions most
urgently needed to prevent occupational
traumatic injuries. The National
Occupational Research Agenda for
Traumatic Injury Prevention provides a
vehicle for industry stakeholders to
describe the most relevant issues, gaps,
and safety and health needs for the
cross-sector. Each NORA research
agenda is meant to guide or promote
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
1,187
930
744
27
27
Average
burden per
response
(in hours)
1
1
1
1
1
52/60
45/60
45/60
90/60
90/60
high priority research efforts on a
national level, conducted by various
entities, including government, higher
education, and the private sector.
This is the first Traumatic Injury
Prevention Agenda, developed for the
third decade of NORA (2016–2026). The
Agenda was developed considering
information about injuries, the state of
the science, and the probability that
new information and approaches will
make a difference.
As the steward of the NORA process,
NIOSH invites comments on the draft
National Occupational Research
Agenda for Traumatic Injury
Prevention. Comments expressing
support or with specific
recommendations to improve the
Agenda are requested. A copy of the
draft Agenda is available at https://
www.regulations.gov (search Docket
Number CDC–2017–0104).
Frank Hearl,
Chief of Staff, National Institute for
Occupational Safety and Health, Centers for
Disease Control and Prevention.
[FR Doc. 2017–26359 Filed 12–6–17; 8:45 am]
BILLING CODE 4163–19–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Submission for OMB Review;
Comment Request
Title: Annual Statistical Report on
Children in Foster Homes and Children
in Families Receiving Payment in
Excess of the Poverty Income Level from
a State Program Funded under Part A of
Title IV of the Social Security Act.
OMB No.: 0970–0004.
Description: The Department of
Health and Human Services is required
to collect these data under section 1124
of Title I of the Elementary and
Secondary Education Act of 1965, as
amended by Public Law 114–95. The
data are used by the U.S. Department of
Education for allocation of funds for
programs to aid disadvantaged
E:\FR\FM\07DEN1.SGM
07DEN1
]]>Agencies
[Federal Register Volume 82, Number 234 (Thursday, December 7, 2017)]
[Notices]
[Pages 57757-57758]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-26399]
[[Page 57757]]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-17-17ACE]
Agency Forms Undergoing Paperwork Reduction Act Review
In accordance with the Paperwork Reduction Act of 1995, the Centers
for Disease Control and Prevention (CDC) has submitted the information
collection request titled Medication-Assisted Treatment (MAT) for
Opioid Use Disorders Study to the Office of Management and Budget (OMB)
for review and approval. CDC previously published a ``Proposed Data
Collection Submitted for Public Comment and Recommendations'' notice on
June, 19, 2017 to obtain comments from the public and affected
agencies. CDC received three comments related to the previous notice.
This notice serves to allow an additional 30 days for public and
affected agency comments.
CDC will accept all comments for this proposed information
collection project. The Office of Management and Budget is particularly
interested in comments that:
(a) Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
(b) Evaluate the accuracy of the agencies estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and clarity of the information to
be collected;
(d) Minimize the burden of the collection of information on those
who are to respond, including, through the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology, e.g., permitting
electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570 or send an email to omb@cdc.gov. Direct written comments
and/or suggestions regarding the items contained in this notice to the
Attention: CDC Desk Officer, Office of Management and Budget, 725 17th
Street NW., Washington, DC 20503 or by fax to (202) 395-5806. Provide
written comments within 30 days of notice publication.
Proposed Project
Evaluation of Medication-Assisted Treatment (MAT) for Opioid Use
Disorder--New--National Center for Injury Prevention and Control
(NCIPC), Centers for Disease Control and Prevention (CDC).
Background and Brief Description
This is a new Information Collection Request. CDC requests a three-
year OMB approval.
About 2 million people aged 12 or older in the United States have
Opioid Use Disorders (OUDs) related to prescription opioids and almost
600,000 have OUDs related to heroin use (SAMHSA, 2015). OUD is a
problematic pattern of opioid use that cause significant impairment or
distress characterized by unsuccessful efforts to control use and
failures to fulfill obligations social, at work, or school, yet many of
these people do not receive OUD treatment. Given the continued need for
treatment and the urgency of the opioid epidemic, further understanding
of the individual and contextual factors that may impact treatment
outcomes is needed. To help address this need, the CDC is conducting a
study of 60 Opioid Use Disorder (OUD) treatment facilities and four
primary care facilities located in 11 metropolitan statistical areas
across the United States. The respondent universe includes individuals
in the United States who receive some form of OUD treatment in the 11
MSAs.
Prospective participants will be eligible if they are 18 to 64
years of age and initiating one of four primary treatments for OUD:
Methadone maintenance treatment (MMT), buprenorphine (BUP), naltrexone
(NTX), or counseling treatment without medication (COUN). The study
aims to enroll 3,560 clients across all sites to better understand the
relationship between type of Medication Assisted Treatment (MAT) and
individual and treatment facility characteristics, and contextual
factors.
The information gained from this data collection will help inform
policy makers, communities, and providers on how individual
characteristics and contextual factors may impact client outcomes. The
MAT study will also provide a unique perspective for three reasons: (1)
It assesses the treatment, individual, and contextual factors that
influence implementation and outcomes in real-world settings; (2) its
large target sample size (n = 3,560); and, (3) the long follow-up
window (i.e., 24-month follow-up period with clients). CDC has
collaborated with other relevant federal agencies to avoid duplication
and maximize efficiencies in data collection. The MAT Study design and
protocols have been reviewed and shared with colleagues from the
Substance Abuse and Mental Health Services Administration (SAMHSA) and
the National Institute on Drug Abuse (NIDA).
Four overarching evaluation questions guide the MAT Study. These
questions drive the research design, and CDC developed this data
collection effort to, specifically, address these evaluation questions.
This data collection effort captures a series of outcome measures
including the associated benefits (e.g., reductions in morbidity,
mortality, and drug overdoses; improvements in socioeconomic outcomes
and health-related quality of life [HRQOL]) and potential risks (e.g.,
side effects, diversion potential) of each treatment alternative.
The study will use a mixed-methods approach using quantitative
methods such as multilevel latent growth models, propensity score
matching, latent class analysis and advanced mediation analysis and
qualitative methods such as interactive coding and analysis for common
themes.
The total estimated annualized burden for this collection is 3,093
hours. The only cost to respondents will be time spent responding to
the surveys.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondents Form name Number of responses per per response
respondents respondent (in hours)
----------------------------------------------------------------------------------------------------------------
Clients............................... Client Screener......... 1,583 1 5/60
Client Check-In......... 1,187 2 15/60
[[Page 57758]]
Client Questionnaire 1,187 1 52/60
Baseline.
Client Questionnaire 12- 930 1 45/60
Month Follow-up.
Client Questionnaire 24- 744 1 45/60
Month Follow-up.
Client Focus Groups..... 27 1 90/60
Treatment facility staff.............. Staff Focus Groups...... 27 1 90/60
----------------------------------------------------------------------------------------------------------------
Leroy A. Richardson,
Chief, Information Collection Review Office, Office of Scientific
Integrity, Office of the Associate Director for Science, Office of the
Director, Centers for Disease Control and Prevention.
[FR Doc. 2017-26399 Filed 12-6-17; 8:45 am]
BILLING CODE 4163-18-P
